Shanghai Haohai Biological Technology Co Ltd 2021 AR2
The report outlines Shanghai Haohai Biological Technology's financial and ESG performance for the fiscal year 2021. The company established a three-level ESG governance structure consisting of the ESG working group, the Audit Committee, and the Board to ensure orderly implementation of sustainability initiatives. Key highlights include a 32.14% increase in revenue to RMB 1,750.12 million and a significant expansion of its product portfolio in ophthalmology and medical aesthetics. On the environmental front, the company successfully obtained ISO 14001 certification and implemented a reclaimed water reuse system at its Songjiang site, saving approximately 12,995 tonnes of water.
Company: Shanghai Haohai Biological Technology Co Ltd
Sector: Manufacturing
Country: China
Year: 2021
Type: AR2
Pages: 231
Shanghai Haohai Biological Technology Co Ltd
The report outlines Shanghai Haohai Biological Technology's financial and ESG performance for the fiscal year 2021. The company established a three-level ESG governance structure consisting of the ESG working group, the Audit Committee, and the Board to ensure orderly implementation of sustainability initiatives. Key highlights include a 32.14% increase in revenue to RMB 1,750.12 million and a significant expansion of its product portfolio in ophthalmology and medical aesthetics. On the environmental front, the company successfully obtained ISO 14001 certification and implemented a reclaimed water reuse system at its Songjiang site, saving approximately 12,995 tonnes of water.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Women on Board
Workplace Fatalities
Employees